Hogan Lovells Represents Elastagen in Sale to Allergan
Hogan Lovells represented Elastagen Pty Ltd., a clinical stage company developing medical device products based on recombinant tropoelastin, in its acquisition by Allergan, a leading global biopharmaceutical company.
Under the terms of the agreement, Sydney, Australia-based Elastagen will receive an upfront payment of about $95 million plus contingent payments of up to $165 million. Completion of the transition is subject to customary closing conditions, including review by Australia’s Foreign Investment Review Board.